Bicycle Therapeutics Plc - ADR

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates. “We are pleased with the progress of our wholly owned clinical oncology pipeline of Bicycle Toxin Conjugate, or BTC™, programs and Bicycle tumor-targe

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting data using tris-Gold complexes to increase the chemical diversity of Bicycles, was published in Bioconjugate Chemistry. The article, titled “Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constr

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist® (Bicycle TICA™) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry. The article, titled “Discov

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised its second option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncolog

Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration

BCYC was founded by a Nobel Prize winner. Hopefully, that will not be its only claim to fame.

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the expansion portion of the Phase I/II study of BT5528, Bicycle's second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2. “We believe EphA2 is an attractive target for cytotoxin delivery and BT5528 has

Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present a Trials in Progress poster highlighting the Phase I/II clinical trial of BT7480, a novel, fully synthetic Bicycle TICA™ targeting Nectin-4 and agonizing CD137, at the 2022 American Society of Clinical Oncology (ASCO) A

Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2022 and provided recent corporate updates. “We have made significant progress recently across our oncology pipeline,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “We

Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC) is down 30% after the biotech firm pioneering novel and differentiated therapeutics class based on its bicyclin peptide tech announced preliminary first phase results from the Phase 1/2 study of BT8009. BT8009 is a second-generation BTC targeting Nectin-4 that the company is developing.

Bicycle Therapeutics reports promising BT8009 study results, shares tank 30%

Lackluster clinical trial results for its lead candidate are to blame.

Here's Why Bicycle Therapeutics Stock Looks Ill Today

Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?

Shares of Bicycle Therapeutics Inc. BCYC, +24.54% tumbled 23.4% in premarket trading on Monday after the company shared interim data from a Phase 1 clinical trial for its urothelial-cancer treatment. Bicycle said its experimental therapy, BT8009, had a 50% overall response rate, and one of the eight patients enrolled in the study who received the smallest dose of the therapy reported a complete response.

Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4. The results were presented in an oral presentation on Sunday, April 10 at the 2022 American Association for Cancer Research Annual Meeting in N

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors. The data will be presented at the 2022 American Association for Cancer Research.

Why Bicycle Therapeutics Stock Is Soaring Today

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA. The

Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated preclinical results providing further evidence for Bicycles as a potential novel antiviral modality against SARS-CoV-2. The results will be presented in an oral presentation today at the 2022 Microbiology Society Annual Meeting in Dublin, Ir

Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 8:45 a.m. ET. A live webcast of the fireside chat will be accessible in the Investors and Media section of B

Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference

Shares of Bicycle Therapeutics have risen by 68% over the past 12 months and 252% over the past 3 years.

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting, being held April

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 8:00 a.m. ET. The conference will be held in a virtual meeting format. A live webcast of the fireside chat will be

Bicycle Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided recent corporate updates. “We are encouraged by the progress we continue to make across our oncology pipeline,” said Kevin Lee, Ph.D., Chief Executive Office

Bicycle Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BT8009 test results conformed to preliminary data suggesting it to be an effective treatment for tumors. BT7480 is currently advancing its phase I clinical trials, and CEO Dr. Kevin Lee said he is pleased with the progress.

Bicycle Therapeutics: An Oncology Play With Big Potential

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 9:20 a.m. ET. The conference will be held in a virtual meeting format. A live webcast of the fireside chat will b

Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

argenx

BridgeBio Pharma Inc

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced continued progress in its ongoing Phase I/II clinical trials of BT8009, BT5528 and BT7480. “Last quarter, we reported interim clinical results from ongoing trials of two of our Bicycle toxin conjugates, BT8009 and BT5528, demonstrating preliminary

News for Bicycle Therapeutics Plc - ADR Stock (BCYC)